• 1
    Kay AB. Allergy and allergic diseases. Second of two parts. N Engl J Med 2001;344:109113.
  • 2
    Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001;344:3037.
  • 3
    Strachan DP. Lifestyle and atopy. Lancet 1999;353:14571458.
  • 4
    Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860876.
  • 5
    Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361:151160.
  • 6
    Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813824.
  • 7
    Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832836.
  • 8
    Illi S, Von ME, Lau S, Nickel R, Gruber C, Niggemann B et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004;113:925931.
  • 9
    Kekki OM, Turjanmaa K, Isolauri E. Differences in skin-prick and patch-test reactivity are related to the heterogeneity of atopic eczema in infants. Allergy 1997;52:755759.
  • 10
    Darsow U, Vieluf D, Ring J. The atopy patch test: an increased rate of reactivity in patients who have an air-exposed pattern of atopic eczema. Br J Dermatol 1996;135:182186.
  • 11
    Niggemann B. The role of the atopy patch test (APT) in diagnosis of food allergy in infants and children with atopic dermatitis. Pediatr Allergy Immunol 2001;12(Suppl. 14):3740.
  • 12
    Turjanmaa K, Darsow U, Niggemann B, Rance F, Vanto T, Werfel T. EAACI/GA2LEN position paper: present status of the atopy patch test. Allergy 2006;61:13771384.
  • 13
    Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152169.
  • 14
    Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006;61:969987.
  • 15
    Schultz Larsen FV, Holm NV. Atopic dermatitis in a population based twin series. Concordance rates and heritability estimation. Acta Derm Venereol Suppl (Stockh) 1985;114:159.
  • 16
    Larsen FS, Holm NV, Henningsen K. Atopic dermatitis. A genetic–epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1986;15:487494.
  • 17
    Cookson W. The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004;4:978988.
  • 18
    Hoffjan S, Epplen JT. The genetics of atopic dermatitis: recent findings and future options. J Mol Med 2005;83:682692.
  • 19
    Maintz L, Novak N. Getting more and more complex: the pathophysiology of atopic eczema. Eur J Dermatol 2007;17:267283.
  • 20
    Lee YA, Wahn U, Kehrt R, Tarani L, Businco L, Gustafsson D et al. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet 2000;26:470473.
  • 21
    Cookson WO, Ubhi B, Lawrence R, Abecasis GR, Walley AJ, Cox HE et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 2001;27:372373.
  • 22
    Bradley M, Soderhall C, Luthman H, Wahlgren CF, Kockum I, Nordenskjold M. Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. Hum Mol Genet 2002;11:15391548.
  • 23
    Haagerup A, Bjerke T, Schiotz PO, Dahl R, Binderup HG, Tan Q et al. Atopic dermatitis – a total genome-scan for susceptibility genes. Acta Derm Venereol 2004;84: 346352.
  • 24
    Gupta J, Grube E, Ericksen MB, Stevenson MD, Lucky AW, Sheth AP et al. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity. J Allergy Clin Immunol 2008;121:725730.
  • 25
    Kezic S, Kemperman PM, Koster ES, De Jongh CM, Thio HB, Campbell LE et al. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol 2008;128:21172119.
  • 26
    McGrath JA, Uitto J. The filaggrin story: novel insights into skin-barrier function and disease. Trends Mol Med 2008;14:2027.
  • 27
    Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441446.
  • 28
    Baurecht H, Irvine AD, Novak N, Illig T, Buhler B, Ring J et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007;120:14061412.
  • 29
    Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, Az-Lacava A et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006; 118: 214219.
  • 30
    Weidinger S, Rodriguez E, Stahl C, Wagenpfeil S, Klopp N, Illig T et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 2007;127:724726.
  • 31
    Bisgaard H, Simpson A, Palmer CN, Bonnelykke K, McLean I, Mukhopadhyay S et al. Gene–environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. PLoS Med 2008;5:e131.
  • 32
    Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B, Lawrence R et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet 2001;29:175178.
  • 33
    Vasilopoulos Y, Cork MJ, Murphy R, Williams HC, Robinson DA, Duff GW et al. Genetic association between an AACC insertion in the 3’UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol 2004;123:6266.
  • 34
    Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008; 121: 13371343.
  • 35
    Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296:298300.
  • 36
    Kabelitz D, Medzhitov R. Innate immunity – cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol 2007;19:13.
  • 37
    Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004;5:975979.
  • 38
    Murray PJ. NOD proteins: an intracellular pathogen-recognition system or signal transduction modifiers? Curr Opin Immunol 2005;17:352358.
  • 39
    Eder W, Klimecki W, Yu L, Von ME, Riedler J, Braun-Fahrlander C et al. Association between exposure to farming, allergies and genetic variation in CARD4/NOD1. Allergy 2006;61:11171124.
  • 40
    Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, Klotz M, Werfel T, Herz U et al. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 2004;113:565567.
  • 41
    Mrabet-Dahbi S, Dalpke AH, Niebuhr M, Frey M, Draing C, Brand S et al. The toll-like receptor 2 R753Q mutation modifies cytokine production and toll-like receptor expression in atopic dermatitis. J Allergy Clin Immunol 2008;121:10131019.
  • 42
    Hoffjan S, Stemmler S, Parwez Q, Petrasch-Parwez E, Arinir U, Rohde G et al. Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med Genet 2005;6:34.
  • 43
    Weidinger S, Novak N, Klopp N, Baurecht H, Wagenpfeil S, Rummler L et al. Lack of association between toll-like receptor 2 and toll-like receptor 4 polymorphisms and atopic eczema. J Allergy Clin Immunol 2006;118: 277279.
  • 44
    Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, Hart J et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 2007;62:766772.
  • 45
    Weidinger S, Klopp N, Rummler L, Wagenpfeil S, Novak N, Baurecht HJ et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J Allergy Clin Immunol 2005;116:177184.
  • 46
    McGirt LY, Beck LA. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol 2006;118:202208.
  • 47
    Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:32623269.
  • 48
    Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347: 11511160.
  • 49
    Howell MD. The role of human beta defensins and cathelicidins in atopic dermatitis. Curr Opin Allergy Clin Immunol 2007;7:413417.
  • 50
    Howell MD, Novak N, Bieber T, Pastore S, Girolomoni G, Boguniewicz M et al. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol 2005;125:738745.
  • 51
    Howell MD, Boguniewicz M, Pastore S, Novak N, Bieber T, Girolomoni G et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 2006;121:332338.
  • 52
    Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836841.
  • 53
    Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003;112(6 Suppl.):S128S139.
  • 54
    Steinke JW, Borish L, Rosenwasser LJ. 5. Genetics of hypersensitivity. J Allergy Clin Immunol 2003;111(2 Suppl.):S495S501.
  • 55
    Wollenberg A, Klein E. Current aspects of innate and adaptive immunity in atopic dermatitis. Clin Rev Allergy Immunol 2007;33:3544.
  • 56
    Novak N, Kruse S, Kraft S, Geiger E, Kluken H, Fimmers R et al. Dichotomic nature of atopic dermatitis reflected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the interleukin-4/interleukin-13 receptor gene: the dichotomy of extrinsic and intrinsic atopic dermatitis. J Invest Dermatol 2002;119: 870875.
  • 57
    Weidinger S, Klopp N, Wagenpfeil S, Rummler L, Schedel M, Kabesch M et al. Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. J Med Genet 2004;41:658663.
  • 58
    Novak N, Kruse S, Potreck J, Maintz L, Jenneck C, Weidinger S et al. Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema. J Allergy Clin Immunol 2005;115: 828833.
  • 59
    Vercelli D. Genetic regulation of IgE responses: achilles and the tortoise. J Allergy Clin Immunol 2005; 116: 6064.
  • 60
    Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005;23:749786.
  • 61
    Marone G, Triggiani M, De PA. Mast cells and basophils: friends as well as foes in bronchial asthma? Trends Immunol 2005;26:2531.
  • 62
    Kraft S, Kinet JP. New developments in FcεRI regulation, function and inhibition. Nat Rev Immunol 2007;7:365378.
  • 63
    Kraft S, Novak N. Fc receptors as determinants of allergic reactions. Trends Immunol 2006;27:8895.
  • 64
    Novak N, Kraft S, Bieber T. IgE receptors. Curr Opin Immunol 2001;13:721726.
  • 65
    Morar N, Willis-Owen SA, Moffatt MF, Cookson WO. The genetics of atopic dermatitis. J Allergy Clin Immunol 2006;118:2434.
  • 66
    Allam JP, Klein E, Bieber T, Novak N. Transforming growth factor-beta1 regulates the expression of the high-affinity receptor for IgE on CD34 stem cell-derived CD1a dendritic cells in vitro. J Invest Dermatol 2004;123:676682.
  • 67
    Novak N, Tepel C, Koch S, Brix K, Bieber T, Kraft S. Evidence for a differential expression of the FcεRIgamma chain in dendritic cells of atopic and nonatopic donors. J Clin Invest 2003;111:10471056.
  • 68
    Novak N, Kraft S, Haberstok J, Geiger E, Allam P, Bieber T. A reducing microenvironment leads to the generation of FcεRIhigh inflammatory dendritic epidermal cells (IDEC). J Invest Dermatol 2002;119:842849.
  • 69
    Wollenberg A, Wen S, Bieber T. Langerhans cell phenotyping: a new tool for differential diagnosis of inflammatory skin diseases [letter]. Lancet 1995;346:16261627.
  • 70
    Kerschenlohr K, Decard S, Przybilla B, Wollenberg A. Atopy patch test reactions show a rapid influx of inflammatory dendritic epidermal cells in patients with extrinsic atopic dermatitis and patients with intrinsic atopic dermatitis. J Allergy Clin Immunol 2003;111:869874.
  • 71
    Wollenberg A, Kraft S, Hanau D, Bieber T. Immunomorphological and ultrastructural characterization of langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996;106:446453.
  • 72
    Stary G, Bangert C, Stingl G, Kopp T. Dendritic cells in atopic dermatitis: expression of FcεRI on two distinct inflammation-associated subsets. Int Arch Allergy Immunol 2005;138: 278290.
  • 73
    Novak N, Allam P, Geiger E, Bieber T. Characterization of monocyte subtypes in the allergic form of atopic eczema/dermatitis syndrome. Allergy 2002;57:931935.
  • 74
    Gombert M, Eu-Nosjean MC, Winterberg F, Bunemann E, Kubitza RC, Da CL et al. CCL1–CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol 2005;174:50825091.
  • 75
    Gunther C, Bello-Fernandez C, Kopp T, Kund J, Carballido-Perrig N, Hinteregger S et al. CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells. J Immunol 2005;174:17231728.
  • 76
    Pivarcsi A, Gombert M, Eu-Nosjean MC, Lauerma A, Kubitza R, Meller S et al. CC chemokine ligand 18, an atopic dermatitis-associated and dendritic cell-derived chemokine, is regulated by staphylococcal products and allergen exposure. J Immunol 2004;173: 58105817.
  • 77
    Schuller E, Oppel T, Bornhovd E, Wetzel S, Wollenberg A. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol 2004;114: 137143.
  • 78
    Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 2004; 114: 887895.
  • 79
    Novak N, Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic dermatitis. J Am Acad Dermatol 2005;2(Suppl. 2):S171S176.
  • 80
    Novak N, Valenta R, Bohle B, Laffer S, Haberstok J, Kraft S et al. FcεRI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J Allergy Clin Immunol 2004;113: 949957.
  • 81
    Novak N, Allam JP, Hagemann T, Jenneck C, Laffer S, Valenta R et al. Characterization of FcεRI-bearing CD123 blood dendritic cell antigen-2 plasmacytoid dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2004;114:364370.
  • 82
    Schroeder JT, Bieneman AP, Xiao H, Chichester KL, Vasagar K, Saini S et al. TLR9- and FcεRI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression. J Immunol 2005;175:57245731.
  • 83
    Szabo G, Dolganiuc A. The role of plasmacytoid dendritic cell-derived IFNalpha in antiviral immunity. Crit Rev Immunol 2008;28:6194.
  • 84
    Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, Moderer M et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002;119:10961102.
  • 85
    Peng WM, Jenneck C, Bussmann C, Bogdanow M, Hart J, Leung DY et al. Risk factors of atopic dermatitis patients for eczema herpeticum. J Invest Dermatol 2007; 127: 12611263.
  • 86
    Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003;49:198205.
  • 87
    Zeller S, Glaser AG, Vilhelmsson M, Rhyner C, Crameri R. Immunoglobulin-E-mediated reactivity to self antigens: a controversial issue. Int Arch Allergy Immunol 2008;145:8793.
  • 88
    Mothes N, Niggemann B, Jenneck C, Hagemann T, Weidinger S, Bieber T et al. The cradle of IgE autoreactivity in atopic eczema lies in early infancy. J Allergy Clin Immunol 2005;116: 706709.
  • 89
    Schmid-Grendelmeier P, Fluckiger S, Disch R, Trautmann A, Wuthrich B, Blaser K et al. IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol 2005;115:10681075.
  • 90
    Mittermann I, Reininger R, Zimmermann M, Gangl K, Reisinger J, Aichberger KJ et al. The IgE-reactive autoantigen Hom s 2 induces damage of respiratory epithelial cells and keratinocytes via induction of IFN-gamma. J Invest Dermatol 2008;128:14511459.
  • 91
    Aichberger KJ, Mittermann I, Reininger R, Seiberler S, Swoboda I, Spitzauer S et al. Hom s 4, an IgE-reactive autoantigen belonging to a new subfamily of calcium-binding proteins, can induce Th cell type 1-mediated autoreactivity. J Immunol 2005;175:12861294.
  • 92
    Kinaciyan T, Natter S, Kraft D, Stingl G, Valenta R. IgE autoantibodies monitored in a patient with atopic dermatitis under cyclosporin A treatment reflect tissue damage. J Allergy Clin Immunol 2002;109:717719.
  • 93
    Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337: 816821.
  • 94
    Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:539546.
  • 95
    Ring J, Abraham A, De CC, Kim K, Langeland T, Parra V et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a >2000 patient study. J Eur Acad Dermatol Venereol 2008;22:195203.
  • 96
    Gollnick H, Kaufmann R, Stough D, Heikkila H, Andriano K, Grinienko A et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol 2008;158:10831093.
  • 97
    Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, Gold MH, Kirsner RS et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008;58:990999.
  • 98
    Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008;63:742750.
  • 99
    Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol 2004;13: 721730.
  • 100
    Simon D, Vassina E, Yousefi S, Braathen LR, Simon HU. Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 2005;60:944951.
  • 101
    Trautmann A, Akdis M, Schmid-Grendelmeier P, Disch R, Brocker EB, Blaser K et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001;108:839846.
  • 102
    Eberlein-Konig B, Michel G, Ruzicka T, Przybilla B. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. Arch Dermatol Res 1997;289:606608.
  • 103
    Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000;136: 9991006.
  • 104
    Simon D, Lindberg RL, Kozlowski E, Braathen LR, Simon HU. Epidermal caspase-3 cleavage associated with interferon-gamma-expressing lymphocytes in acute atopic dermatitis lesions. Exp Dermatol 2006;15: 441446.
  • 105
    Hoetzenecker W, Meindl S, Stuetz A, Stingl G, Elbe-Burger A. Both pimecrolimus and corticosteroids deplete plasmacytoid dendritic cells in patients with atopic dermatitis. J Invest Dermatol 2006;126: 21412144.
  • 106
    Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001;107:345352.
  • 107
    Ma W, Mishra S, Gee K, Mishra JP, Nandan D, Reiner NE et al. Cyclosporin A and FK506 inhibit IL-12p40 production through the calmodulin/calmodulin-dependent protein kinase-activated phosphoinositide 3-kinase in lipopolysaccharide-stimulated human monocytic cells. J Biol Chem 2007;282:1335113362.
  • 108
    Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Investig Med 2001;49:442449.
  • 109
    Kwiek B, Peng WM, Allam JP, Langner A, Bieber T, Novak N. Tacrolimus and TGF-beta act synergistically on the generation of Langerhans cells. J Allergy Clin Immunol 2008;122:126132.
  • 110
    Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006;61:202205.
  • 111
    Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006;118:12921298.
  • 112
    Bussmann C, Maintz L, Hart J, Allam JP, Vrtala S, Chen KW et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007;37:12771285.
  • 113
    Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:12231225.
  • 114
    Lim A, Luderschmidt S, Weidinger A, Schnopp C, Ring J, Hein R et al. The IgE repertoire in PBMCs of atopic patients is characterized by individual rearrangements without variable region of the heavy immunoglobulin chain bias. J Allergy Clin Immunol 2007;120:696706.
  • 115
    Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122128.
  • 116
    Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007;56:222227.
  • 117
    Harper EG, Simpson EL, Takiguchi RH, Boyd MD, Kurtz SE, Bakke AC et al. Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. J Invest Dermatol 2008;128:11731181.
  • 118
    Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198208.
  • 119
    Di ML, Centi C, Cinque B, Masci S, Giuliani M, Arcieri A et al. Effect of the lactic acid bacterium Streptococcus thermophilus on stratum corneum ceramide levels and signs and symptoms of atopic dermatitis patients. Exp Dermatol 2003;12:615620.